Brainstorm Cell Therapeutics (BCLI) Tops Q1 EPS by 3c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q1 EPS of ($0.14), $0.03 better than the analyst estimate of ($0.17).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
• Jones Trading Starts Pershing Square Inc (PS) at Buy
• Raymond James Upgrades Dollar Tree (DLTR) to Outperform